<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05047874</url>
  </required_header>
  <id_info>
    <org_study_id>BIRUNI 1</org_study_id>
    <nct_id>NCT05047874</nct_id>
  </id_info>
  <brief_title>High-dose, Short-term Steroid and Low-dose Long-term Steroid Use in ARDS Caused by COVID-19</brief_title>
  <official_title>Comparison of High-dose, Short-term Steroid and Low-dose Long-term Steroid Use in ARDS Caused by COVID-19 - Retrospective Cross-sectional Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biruni University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biruni University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study, we aimed to compare, retrospectively, the 15-day continuous hemodynamic,&#xD;
      laboratory and clinical course of COVID 19 patients to whom we administered short-term (3&#xD;
      days) high-dose (1000 mg) systemic methylprednisolone with those to whom low-dose long-term&#xD;
      (2x 40 mg) systemic methylprednisolone was administered.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">September 20, 2021</start_date>
  <completion_date type="Anticipated">October 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">October 20, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>C Reaktif Protein</measure>
    <time_frame>15 DAYS</time_frame>
    <description>level of C Reaktif Protein</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Short-term (3 Days) High-dose (1000 mg) Systemic Methylprednisolone</condition>
  <arm_group>
    <arm_group_label>short-term (3 days) high-dose (1000 mg) systemic methylprednisolone</arm_group_label>
    <description>retrospectively, the 15-day continuous hemodynamic, laboratory and clinical course of COVID 19 patients to whom we administered short-term (3 days) high-dose (1000 mg) systemic methylprednisolone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>low-dose long-term (2x 40 mg) systemic methylprednisolone</arm_group_label>
    <description>retrospectively, the 15-day continuous hemodynamic, laboratory and clinical course of COVID 19 patients to whom low-dose long-term (2x 40 mg) systemic methylprednisolone</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>systemic methylprednisolone</intervention_name>
    <description>short-term (3 days) high-dose (1000 mg) systemic methylprednisolone and low-dose long-term (2x 40 mg) systemic methylprednisolone</description>
    <arm_group_label>low-dose long-term (2x 40 mg) systemic methylprednisolone</arm_group_label>
    <arm_group_label>short-term (3 days) high-dose (1000 mg) systemic methylprednisolone</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        File records of patients over the age of 18 who were admitted to the General intensive care&#xD;
        unit of Biruni University Medical Faculty Hospital between 1 June 2020 and 1 February 2021&#xD;
        with the diagnosis of COVID 19&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Between June 1, 2020 and February 1, 2021, hospitalized in the General intensive care&#xD;
             unit of Biruni University Medical Faculty Hospital with the diagnosis of COVID 19;&#xD;
&#xD;
          -  patients over 18 years of age; (for the diagnosis of COVID 19; Identification of&#xD;
             SARS-CoV-2 by reverse transcription-polymerase chain reaction (RT-PCR) in&#xD;
             nasopharyngeal swab or sputum samples and Abnormal lung computed tomography finding&#xD;
             (CT) scan finding with &lt;90% oxygen saturation at rest (bilateral, subpleural,&#xD;
             peripheral ground glass opacities)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with a diagnosis of steroid allergy or developing during treatment;&#xD;
&#xD;
          -  pregnant or lactating women;&#xD;
&#xD;
          -  Patients with active malignancy;&#xD;
&#xD;
          -  Patients taking any immunosuppressive agent.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>105 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>ilke kupeli</last_name>
    <phone>+905555485632</phone>
    <email>ilkeser2004@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ilke Kupeli</name>
      <address>
        <city>Istanbul</city>
        <zip>24100</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>ilke kupeli</last_name>
      <phone>05555485632</phone>
      <email>ilkeser2004@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <reference>
    <citation>Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ; HLH Across Speciality Collaboration, UK. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020 Mar 28;395(10229):1033-1034. doi: 10.1016/S0140-6736(20)30628-0. Epub 2020 Mar 16.</citation>
    <PMID>32192578</PMID>
  </reference>
  <reference>
    <citation>Buttgereit F, Straub RH, Wehling M, Burmester GR. Glucocorticoids in the treatment of rheumatic diseases: an update on the mechanisms of action. Arthritis Rheum. 2004 Nov;50(11):3408-17. Review.</citation>
    <PMID>15529366</PMID>
  </reference>
  <results_reference>
    <citation>Rodríguez-Molinero A, Pérez-López C, Gálvez-Barrón C, Miñarro A, Rodríguez Gullello EA, Collado Pérez I, Milà Ràfols N, Mónaco EE, Hidalgo García A, Añaños Carrasco G, Chamero Pastilla A; group of researchers for COVID-19 of the Consorci Sanitari de l'Alt Penedès i Garraf (CSAPG). Association between high-dose steroid therapy, respiratory function, and time to discharge in patients with COVID-19: Cohort study. Med Clin (Engl Ed). 2021 Jan 10;156(1):7-12. doi: 10.1016/j.medcle.2020.08.001. Epub 2020 Nov 27.</citation>
    <PMID>33263084</PMID>
  </results_reference>
  <results_reference>
    <citation>Edalatifard M, Akhtari M, Salehi M, Naderi Z, Jamshidi A, Mostafaei S, Najafizadeh SR, Farhadi E, Jalili N, Esfahani M, Rahimi B, Kazemzadeh H, Mahmoodi Aliabadi M, Ghazanfari T, Sattarian M, Ebrahimi Louyeh H, Raeeskarami SR, Jamalimoghadamsiahkali S, Khajavirad N, Mahmoudi M, Rostamian A. Intravenous methylprednisolone pulse as a treatment for hospitalised severe COVID-19 patients: results from a randomised controlled clinical trial. Eur Respir J. 2020 Dec 24;56(6). pii: 2002808. doi: 10.1183/13993003.02808-2020. Print 2020 Dec.</citation>
    <PMID>32943404</PMID>
  </results_reference>
  <results_reference>
    <citation>Li J, Liao X, Zhou Y, Wang L, Yang H, Zhang W, Zhang Z, Kang Y. Comparison of Associations Between Glucocorticoids Treatment and Mortality in COVID-19 Patients and SARS Patients: A Systematic Review and Meta-Analysis. Shock. 2021 Aug 1;56(2):215-228. doi: 10.1097/SHK.0000000000001738.</citation>
    <PMID>33555845</PMID>
  </results_reference>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 16, 2021</study_first_submitted>
  <study_first_submitted_qc>September 16, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 17, 2021</study_first_posted>
  <last_update_submitted>September 16, 2021</last_update_submitted>
  <last_update_submitted_qc>September 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Biruni University</investigator_affiliation>
    <investigator_full_name>IKUPELI</investigator_full_name>
    <investigator_title>investigator</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Acetate</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

